Absci Corporation (NASDAQ:ABSI) Financings

Absci Corporation

Financings

RaiseDate
Public offering of common stock
Announced: about US$100M · US$7.41 a share · Jefferies +3
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead)
Buyers: Eli Lilly & Company; Adage; BVF Partners; Columbia Threadneedle; Invus; Redmile
Use of proceeds: Advance ABS-201 anti-PRLR antibody in androgenetic alopecia and endometriosis, plus working capital and general corporate purposes
Jun 24, 2026
Public offering of common stock
Announced: US$50M · US$3 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), TD Securities (USA) LLC (co-lead)
Use of proceeds: Advancing internally developed programs, investment in its Integrated Drug Creation platform, working capital and general corporate purposes
Jul 24, 2025
Strategic investment of equity (PIPE)
Announced: US$20M
Buyers: AMD ($20 million investment)
Jan 8, 2025

Read by 6ix AI from the company's releases